Navigation Links
NeuroPhage to Participate in World's First G8 Dementia Summit
Date:12/3/2013

CAMBRIDGE, Mass., Dec. 3, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been invited to participate in the world's first G8 Dementia Summit. The G8 Summit is hosted by the British Prime Minister, David Cameron, and Health Secretary, Jeremy Hunt, and will be attended by G8 Health Ministers, pharmaceutical company leaders, innovators, technology pioneers, breakthrough researchers and investors. The Summit will explore the coordination of efforts to shape an effective international solution to dementia, a condition that affects over 35 million people worldwide, including looking for effective therapies to slow dementia's impact. The G8 Dementia Summit will take place in London, UK, on December 11, 2013.

"We applaud this groundbreaking initiative that the Prime Minister and the Health Secretary have undertaken to bring together leaders from government, research and finance to focus on addressing the enormous health and economic burden that dementia has on patients and families around the world," said Jonathan Solomon, President and Chief Executive Officer of NeuroPhage. "Dementia has proved to be a challenging indication to treat, as the biology behind the various conditions is complex. We are honored to take part in this ambitious international effort in hopes to create a greater collaborative approach worldwide to better achieve our common goals of treating and preventing dementia."

About NeuroPhage  

NeuroPhage Pharmaceuticals has fusion-protein drug candidates in development for neurodegenerative diseases, many of which cause progressive mental deterioration and dementia.  NeuroPhage's technology is based on a General Amyloid Interaction Motif (GAIM) that simultaneously targets multiple misfolded proteins or amyloids central to many neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. In addition to targeting multiple misfolded pathological proteins, this unique disease-modifying approach recognizes early amyloid assemblies and existing protein aggregates to maximize potential therapeutic effect. NeuroPhage is initially developing candidates to treat Alzheimer's and Parkinson's disease, where a number of different misfolded proteins are present and their interactions can exacerbate disease progression.


'/>"/>
SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
2. Uroplasty To Participate In The Piper Jaffray Healthcare Conference
3. Hill-Rom to Participate in the 25th Annual Piper Jaffray Healthcare Conference
4. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
5. Boston Scientific To Participate In 2013 Credit Suisse Healthcare Conference
6. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
7. Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
8. montmed to participate in Vascular 2013
9. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
10. Amgen To Participate At Citis 8th Annual Biotech Conference
11. China Biologic to Participate in Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 ... specialty clinical-stage pharmaceutical company specializing in the development of ... public offering in the United States ... each ADS representing 40 ordinary shares of the ... In addition, Therapix has granted the underwriters a ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... 2017 To mark the end of Save Your ... leader in digital imaging solutions, will showcase Canon eye care ... New York,s Jacob Javits Center from ... sponsored by the American Optometric Association, is observed annually in ... comprehensive eye exams. In recognition of this observance, Canon ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have soared 82% ... Trends Report). As travelers visit both urban destinations, they are faced with exploration ... exposure. In response, the outdoor industry has blurred the lines between fashion and ...
(Date:3/28/2017)... ... 2017 , ... Z-Medica, LLC, a leading developer and marketer ... will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 schools ... by the American College of Surgeons, U.S. Department of Defense, Department of Homeland ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... health plans work, the Self-Funding Success website has recently developed and published an ... Health Plans ” was created based on common inquiries the site’s team of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and ... thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. The ... Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud ...
Breaking Medicine News(10 mins):